Fast Clinical Response With Topical Ruxolitinib in the Management of Non-Segmental Vitiligo Detected by VISIA Analysis System

    December 2025 in “ Dermatology Reports ”
    Alberto Di Caro, Maria Elisabetta Greco, Francesca Paola Sasso, Francesca Feresin, Ilaria Proietti, Giovanni Pellacani, Steven Paul Nisticò, Annunziata Dattola
    TLDR Topical ruxolitinib quickly improves non-segmental vitiligo.
    The document discusses the use of topical ruxolitinib in treating non-segmental vitiligo, a condition marked by the loss of skin pigmentation due to the destruction of melanocytes. The study highlights a fast clinical response to the treatment, as detected by the VISIA® analysis system. Vitiligo often includes leukotrichia, which affects 10% to 60% of patients and involves depigmentation of hair follicles. The findings suggest that topical ruxolitinib could be an effective management option for this chronic disorder.
    Discuss this study in the Community →